ReviewNature reviews. Cancer2025
Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy.
Review in Nature reviews. Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- γδ T cells in colorectal and liver cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Viscoelastic Niches Shape γδ T-Cell Phenotype and Effector Function.bioRxiv : the preprint server for biology · 2026Article
- A Microgel-Based Platform for Tunable Expansion and Function of γδ T-cells.bioRxiv : the preprint server for biology · 2026Article
- Harnessing the potential of γδ T cells through engineering and combination treatment for cancer therapies.Nature communications · 2026Review
- Soluble Sema4D From γδ T Cells Exerts Osteoblast Inhibition via Plexin-B/mTOR Signalling Contributing to Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaws.Cell proliferation · 2026Article
- Commentary on "Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer".Journal for immunotherapy of cancer · 2026Article
- Vitamin C enhances cytotoxicity of CAR-and εTRuC-engineered γδ T cells and modulates CaFrontiers in immunology · 2026Article
- Pre-existing activation states shape functional heterogeneity of human Vγ9Vδ2 T cells.Frontiers in immunology · 2026Article
- Autologous profiling reveals inter-patient heterogeneity in Vδ2Journal for immunotherapy of cancer · 2025Article
- Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD.Hematology. American Society of Hematology. Education Program · 2025Review
- Article
- Regulatory effects of traditional Chinese medicine on the breast-cancer immune microenvironment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
γδT cell biology in cancer has been studied for decades but remains poorly understood mainly due to species differences in preclinical models and a lack of appropriate analytical tools. This lack of knowledge has hindered the clinical translation of promising therapeutic concepts. In recent years, advanced single-cell analysis techniques and comprehensive protein-protein interaction studies have transformed our understanding of γδT cells and their receptors. This insight has revealed new opportunities and challenges in harnessing γδT cells for therapeutic purposes. In this context, we will discuss the latest findings in γδT cell biology, with a special focus on their role in cancer immune therapies. We will explore strategies to overcome tolerance and shift the balance of γδT cells and their receptors towards antitumour efficacy, which has the potential to successfully translate into various engineering approaches in cancer immunotherapy.
Indexed as
Identifiers
40456901What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.